Protalix has obtained approval of Elelyso, its treatment for Type 1 Gaucher disease
Protalix Biotherapeutics Inc. (NYSE MKT:PLX; TASE: PLX) has obtained Health Canada approval of Elelyso, its treatment for Type 1 Gaucher disease in adults and children. Elelyso is a long-term enzyme replacement therapy. Pfizer Inc. (NYSE: PFE; LSE: PFZ) will market the drug in Canada.
"With the Canadian approval of Elelyso, the drug is now approved for patients in more than ten countries across the globe," said Protalix SVP product development Dr. Einat Brill Almon. "This validates the ability and safety of ProCellEx, our manufacturing platform technology, which we are currently using to develop additional enzyme replacement therapies."
Published by Globes [online], Israel business news - www.globes-online.com - on June 1, 2014
© Copyright of Globes Publisher Itonut (1983) Ltd. 2014